Being Selective in Biotech: Carol Werther

The Life Sciences Report: Biotech stocks began the year with a powerful uptick. Is this deserved? Carol Werther: The uptick for the group was well deserved, but it’s hard to predict how long it will last. Last year I felt that the prices of many of the companies I covered were quite depressed for a lot of reasons, and then there was a lot of year-end, tax-loss selling that really kept stocks down. It has been a very difficult and spotty market and it has been very volatile, which is typical in biotech. You have to really pick and choose your winners. But, what surprises me the most is there seems to be real inequality in how people look . . . → Read More: Being Selective in Biotech: Carol Werther